Suppr超能文献

急性心肌梗死溶栓治疗后凝血活性的系列变化

Serial changes in coagulant activities after thrombolytic therapy for acute myocardial infarction.

作者信息

Goto S, Kawai Y, Abe S, Takahashi E, Handa S, Ogawa S, Watanabe K, Hori S, Ikeda Y

机构信息

Cardiopulmonary Division, Keio University School of Medicine, Tokyo, Japan.

出版信息

Angiology. 1994 Apr;45(4):273-81. doi: 10.1177/000331979404500403.

Abstract

Early reocclusion and bleeding complications are still unresolved problems in thrombolytic therapy for acute myocardial infarction (AMI). In the present study, 16 patients treated with either fibrin-specific tissue-type plasminogen activator (t-PA) or nonspecific urokinase (UK) were studied to determine the effects of thrombolytic therapy on serial hemostatic states. Hemostatic states of each patient were estimated by measuring various plasma markers at one- to two-hour intervals during the first six hours of therapy, daily during the next three days, and subsequently on day 7. Two markers of plasma thrombin generation, thrombin antithrombin III complex (TAT) and prothrombin fragment 1 + 2 (F 1 + 2), showed an activated coagulant state immediately after thrombolytic therapy. The amount of thrombin generation indicated by these markers showed significant positive correlation with direct markers of fibrinolysis such as fibrin degradation products (FDP), while it did not show any correlation with the markers for plasmin generation. The potential for coagulation as indicated by prothrombin time (%) decreased with thrombolysis using fibrin nonselective agents, owing perhaps to destruction of coagulant factors by free plasmin. Fibrinolytic activity induced by thrombolytic therapy for AMI caused transient activation of the coagulant system, which could contribute to early reocclusion. Fibrin nonselective agents decreased the potential for coagulation by destroying clotting factor through the generation of free plasmin. These data provide theoretical support for simultaneous administration of anticoagulant therapy with fibrin-specific thrombolytic agents.

摘要

早期再闭塞和出血并发症仍是急性心肌梗死(AMI)溶栓治疗中尚未解决的问题。在本研究中,对16例接受纤维蛋白特异性组织型纤溶酶原激活剂(t-PA)或非特异性尿激酶(UK)治疗的患者进行了研究,以确定溶栓治疗对连续止血状态的影响。在治疗的前6小时内,每隔1至2小时,在接下来的3天内每天,以及随后在第7天,通过测量各种血浆标志物来评估每位患者的止血状态。血浆凝血酶生成的两个标志物,凝血酶抗凝血酶III复合物(TAT)和凝血酶原片段1 + 2(F 1 + 2),在溶栓治疗后立即显示出凝血激活状态。这些标志物所指示的凝血酶生成量与纤维蛋白溶解的直接标志物如纤维蛋白降解产物(FDP)呈显著正相关,而与纤溶酶生成的标志物无任何相关性。使用纤维蛋白非选择性药物进行溶栓时,凝血酶原时间(%)所指示的凝血潜力降低,这可能是由于游离纤溶酶对凝血因子的破坏。AMI溶栓治疗诱导的纤维蛋白溶解活性导致凝血系统短暂激活,这可能导致早期再闭塞。纤维蛋白非选择性药物通过产生游离纤溶酶破坏凝血因子,从而降低凝血潜力。这些数据为纤维蛋白特异性溶栓药物与抗凝治疗同时给药提供了理论支持。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验